To the best of our knowledge, this is the first report suggesting the potential for mTOR kinase inhibitors in rapalogue-(RAD001) insensitive ER+/HER2- breast cancer cells with acquired endocrine resistance. Here, ERBB2 is linked to breast carcinoma.